Plus Therapeutics officer files initial ownership

PLUS THERAPEUTICS, INC. executive Eric Joseph Daniels, Chief Development Officer, filed an initial Form 3 reporting his beneficial ownership of company stock.

Rhea-AI Filing Summary

PLUS THERAPEUTICS, INC. executive Eric Joseph Daniels, Chief Development Officer, filed an initial Form 3 reporting his beneficial ownership of company stock. The filing lists one entry for Common Stock and shows 0 shares owned directly following the reported holdings line.

The transaction section contains no purchases, sales, option exercises, or other transfers, indicating there were no reportable transactions in PLUS Therapeutics stock at the time of this initial ownership statement.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Daniels Eric Joseph

Role Chief Development Officer

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 0 shares (Direct)

Key Figures

Common Stock owned: 0 shares Reported holdings entries: 1 entry Reported buy transactions: 0 transactions +1 more

4 metrics

Common Stock owned 0 shares Direct beneficial ownership following Form 3 holdings entry

Reported holdings entries 1 entry Single Common Stock line item in Form 3

Reported buy transactions 0 transactions Form 3 transactionSummary buyCount

Reported sell transactions 0 transactions Form 3 transactionSummary sellCount

Key Terms

Form 3, Common Stock, Chief Development Officer

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3) for PLUS THERAPEUTICS, INC."

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Common Stock financial

""security_title": "Common Stock" in the reported holdings entry"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Chief Development Officer financial

""officer_title": "Chief Development Officer" for Eric Joseph Daniels"

Chief development officer is the senior executive who leads a company's efforts to create and grow future revenue streams, whether by developing new products, forging partnerships, or running clinical and regulatory programs in research-focused businesses. Investors watch this role because the officer shapes the pipeline and execution that determine future sales and risk — like a head gardener planning and tending crops that will produce tomorrow’s harvest.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the PLUS Therapeutics (PSTV) Form 3 for Eric Joseph Daniels show?

The Form 3 shows Chief Development Officer Eric Joseph Daniels’ initial ownership in PLUS Therapeutics. It reports one line for Common Stock with 0 shares directly owned following the reported holdings, and no purchases, sales, or option exercises disclosed in the filing.

Did Eric Joseph Daniels buy or sell PLUS Therapeutics (PSTV) shares in this Form 3?

No transactions are reported in this Form 3. The filing lists a single holding entry for Common Stock, with transaction counts showing zero buys, zero sells, and zero exercises, indicating no reportable trading activity in PLUS Therapeutics shares at that time.

How many PLUS Therapeutics (PSTV) shares does Eric Joseph Daniels own according to the Form 3?

The Form 3 reports that Eric Joseph Daniels beneficially owns 0 shares of PLUS Therapeutics Common Stock directly following the reported holdings line. This means there is no disclosed direct common stock position as of the filing’s reported date.

What role does Eric Joseph Daniels hold at PLUS Therapeutics (PSTV) in this filing?

In this Form 3, Eric Joseph Daniels is identified as an officer of PLUS Therapeutics with the title Chief Development Officer. The form associates his executive role with the disclosed beneficial ownership information for PLUS Therapeutics Common Stock.

Does the PLUS Therapeutics (PSTV) Form 3 show any derivative securities for Eric Joseph Daniels?

The Form 3 shows no derivative securities for Eric Joseph Daniels. The derivative section is empty, and summary counts indicate zero derivative transactions or remaining derivative positions related to PLUS Therapeutics at the time of this initial ownership report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/21/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Daniels Eric Joseph

(Last) (First) (Middle)

6420 LEVIT GREEN BOULEVARD, SUITE 310

(Street)

HOUSTON TEXAS 77021

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/20/2026

3. Issuer Name and Ticker or Trading Symbol
PLUS THERAPEUTICS, INC. [ PSTV ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	0	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Andrew Sims, attorney-in-fact	04/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)